Il-23
Approved
Il-23 is one of 7 therapeutic programs targeting Ulcerative Colitis (UC). It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
10 competitors in Ulcerative Colitis (UC)
#DrugCompanyPhaseTrials
1Omvoh
Eli LillyApproved
IL-12
PfizerApproved
Ponvory
VVanda Pharmaceuticals
Phase 3
Anti-TNF Agents
AAltuğ Güner
Approved
Anti-Integrin Antibodies
PPeking University First Hospital
Approved
Il-23
SSpecialty Networks Research.
Approved
LY4268989
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Il-23. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Approved[1]
- Company
- SSpecialty Networks Research.